Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference
Kairos Pharma Ltd. will present initial Phase 1 data for its ENV105 combination therapy targeting drug-resistant non-small cell lung cancer at the World Lung Cancer Conference, potentially addressing significant unmet medical needs in oncology treatment.
Kairos Pharma Ltd. (NYSE American: KAPA) announced it will present initial Phase 1 clinical trial data for its experimental cancer treatment ENV105 at the upcoming World Lung Cancer Conference in Barcelona. The presentation, scheduled for September 6-9, 2025, will feature findings from Principal Investigator Dr. Karen Reckamp regarding the combination therapy of ENV105 with osimertinib for advanced EGFR-mutated non-small cell lung cancer patients.
The open-label trial's primary objective focuses on evaluating the safety and tolerability of this novel combination approach. ENV105 represents a significant advancement in cancer therapeutics as it targets CD105, a protein identified as a key driver of resistance to various cancer treatments. The elevation of CD105 in response to standard therapy often results in resistance and disease relapse, making ENV105's mechanism of action particularly important for overcoming treatment limitations.
Kairos Pharma's approach utilizes structural biology to address drug resistance and immune suppression in cancer, positioning the company at the forefront of oncology innovation. The Phase 1 data presentation comes as the company continues to advance ENV105 through clinical development, with the drug also currently in a Phase 2 clinical trial for castrate-resistant prostate cancer. Additional information about the company's developments is available in their newsroom.
The World Lung Cancer Conference presentation marks an important milestone for Kairos Pharma as it seeks to address significant unmet medical needs in lung cancer treatment. The combination therapy approach could potentially restore the effectiveness of standard therapies across multiple cancer types by reversing drug resistance mechanisms. The conference presentation will provide the oncology community with valuable insights into the safety profile and early efficacy signals of this innovative treatment strategy.
InvestorWire, the specialized communications platform that distributed this announcement, provides advanced wire-grade press release syndication services as part of the Dynamic Brand Portfolio that includes access to extensive distribution networks and corporate communications solutions. More details about their services can be found at https://www.InvestorWire.com.